<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02181816</url>
  </required_header>
  <id_info>
    <org_study_id>212-011</org_study_id>
    <secondary_id>JapicCTI-142592</secondary_id>
    <nct_id>NCT02181816</nct_id>
  </id_info>
  <brief_title>Azilsartan/Amlodipine Combination Tablets LD &amp; HD Specified Drug-use Survey &quot;Long-term Use Survey&quot;</brief_title>
  <official_title>Zacras Combination Tablets LD &amp; HD Specified Drug-use Survey &quot;Long-term Use Survey&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this survey is to evaluate the safety and efficacy of long-term use of
      azilsartan/amlodipine combination tablets LD &amp; HD (Zacras Combination Tablets LD &amp; HD) in
      hypertensive patients in daily medical practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This survey was designed to evaluate the safety and efficacy of long-term use of
      azilsartan/amlodipine combination tablets LD &amp; HD (Zacras Combination Tablets LD &amp; HD) in
      hypertensive patients in daily medical practice.

      For adults, one azilsartan/amlodipine combination tablet (20 mg/2.5 mg [for LD tablets] or 20
      mg/5 mg [for HD tablets] of azilsartan/amlodipine) is administered orally once daily.
      Azilsartan/amlodipine combination tablets should not be used as the first-line drug for the
      treatment of hypertension.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 26, 2014</start_date>
  <completion_date type="Actual">January 31, 2017</completion_date>
  <primary_completion_date type="Actual">January 31, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of adverse event</measure>
    <time_frame>12 months</time_frame>
    <description>The frequencies of all adverse events observed during the observation period will be tabulated by type, time of onset, seriousness, and causal relationship to azilsartan/amlodipine combination tablet. Adverse events are defined as any unfavorable and unintended all of signs (including abnormal test values), symptoms or diseases temporally associated with administration of azilsartan/amlodipine combination tablet, whether or not it was considered related to the treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Office blood pressure</measure>
    <time_frame>From baseline to 12 months of treatment</time_frame>
    <description>For the efficacy analysis set, the value of office blood pressure measurements, corresponding changes from baseline, and the rate of change from baseline at each assessment time point will be tabulated</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1090</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Oral administration of azilsartan/amlodipine</arm_group_label>
    <description>Oral administration of azilsartan/amlodipine once daily at a dose of 20 mg/2.5 mg or 20 mg/5 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azilsartan/amlodipine</intervention_name>
    <description>Azilsartan/amlodipine combination tablets LD &amp; HD</description>
    <arm_group_label>Oral administration of azilsartan/amlodipine</arm_group_label>
    <other_name>Zacras Combination Tablets LD &amp; HD</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Hypertension
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hypertensive patients

        Exclusion Criteria:

          -  Hypertensive patients who meet any of the following conditions, [1] to [3], are
             excluded from the survey:

               1. Patients with a history of hypersensitivity to any of the ingredients of Zacras
                  Combination Tablets or other dihydropyridine drugs

               2. Patients who are pregnant or having possibilities of being pregnant

               3. Diabetic patients taking aliskiren fumarate (excluding those with markedly poor
                  blood pressure control even after other antihypertensive treatment)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Postmarketing Group Manager</last_name>
    <role>Study Chair</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2014</study_first_submitted>
  <study_first_submitted_qc>July 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2014</study_first_posted>
  <last_update_submitted>March 23, 2018</last_update_submitted>
  <last_update_submitted_qc>March 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacological therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

